Bethany Girard

2.3k total citations · 1 hit paper
24 papers, 694 citations indexed

About

Bethany Girard is a scholar working on Infectious Diseases, Animal Science and Zoology and Immunology. According to data from OpenAlex, Bethany Girard has authored 24 papers receiving a total of 694 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Infectious Diseases, 8 papers in Animal Science and Zoology and 7 papers in Immunology. Recurrent topics in Bethany Girard's work include SARS-CoV-2 and COVID-19 Research (19 papers), Animal Virus Infections Studies (8 papers) and Viral gastroenteritis research and epidemiology (6 papers). Bethany Girard is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (19 papers), Animal Virus Infections Studies (8 papers) and Viral gastroenteritis research and epidemiology (6 papers). Bethany Girard collaborates with scholars based in United States, Canada and South Africa. Bethany Girard's co-authors include Jacqueline M. Miller, Lindsey R. Baden, Haiyu Zhou, Rituparna Das, Darin K. Edwards, David C. Montefiori, Brandon Essink, Ying Chang, Jing Feng and Spyros Chalkias and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Medicine.

In The Last Decade

Bethany Girard

20 papers receiving 677 citations

Hit Papers

A Bivalent Omicron-Containing Booster Vaccine against Cov... 2022 2026 2023 2024 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Bivalent Omicron-Containing Booster Vaccine against Covid-19
    2022 346 citations Spyros Chalkias, Charles Harper et al. profile →

Peers

Bethany Girard
Ying Chang United States
Alina Seidel Germany
Maegan L. Sheehan United States
Justin DaSilva United States
Angelique Hœlzemer Germany
Onosereme Ofoman South Africa
Cristhian Berrios United States
Meagan E. Deming United States
Ying Chang United States
Bethany Girard
Citations per year, relative to Bethany Girard Bethany Girard (= 1×) peers Ying Chang

Countries citing papers authored by Bethany Girard

Since Specialization
Citations

This map shows the geographic impact of Bethany Girard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bethany Girard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bethany Girard more than expected).

Fields of papers citing papers by Bethany Girard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bethany Girard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bethany Girard. The network helps show where Bethany Girard may publish in the future.

Co-authorship network of co-authors of Bethany Girard

This figure shows the co-authorship network connecting the top 25 collaborators of Bethany Girard. A scholar is included among the top collaborators of Bethany Girard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bethany Girard. Bethany Girard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fierro, Carlos, et al.. (2025). Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study. Frontiers in Immunology. 16. 1501275–1501275.
2.
Bangaru, Sandhya, Abigail M. Jackson, Jeffrey Copps, et al.. (2025). Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines. Cell Reports. 44(7). 115986–115986.
3.
Chalkias, Spyros, Rahnuma Wahid, Darin K. Edwards, et al.. (2025). Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial. The Lancet Infectious Diseases. 25(11). 1230–1242. 6 indexed citations
4.
Girard, Bethany, Amparo L. Figueroa, Stephen C. De Rosa, et al.. (2025). mRNA-1273 COVID-19 vaccine induces CD4+ T-cell responses among solid organ transplant recipients. Frontiers in Immunology. 16. 1505871–1505871.
5.
Rostad, Christina A., James D. Campbell, Grant Paulsen, et al.. (2025). Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age. The Journal of Infectious Diseases. 231(5). e945–e955. 2 indexed citations
6.
Figueroa, Amparo L., Bethany Girard, Darin K. Edwards, et al.. (2025). Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants. Open Forum Infectious Diseases. 12(12). ofaf705–ofaf705. 1 indexed citations
7.
Priddy, Frances, Spyros Chalkias, Brandon Essink, et al.. (2024). A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children. Expert Review of Vaccines. 23(1). 862–878. 6 indexed citations
8.
Figueroa, Amparo L., Jamil Azzi, Bijan Eghtesad, et al.. (2024). Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients. The Journal of Infectious Diseases. 230(3). e591–e600. 3 indexed citations
9.
Figueroa, Amparo L., Anne Yeakey, Weiping Deng, et al.. (2024). Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial. The Lancet Infectious Diseases. 25(2). 208–217. 1 indexed citations
10.
Figueroa, Amparo L., Gary Berman, Haiyu Zhou, et al.. (2024). Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial. EClinicalMedicine. 74. 102720–102720. 5 indexed citations
11.
Chalkias, Spyros, Nichole McGhee, Brandon Essink, et al.. (2024). Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines. The Journal of Infectious Diseases. 230(2). e279–e286. 36 indexed citations
12.
Ivaturi, Vijay, Husain Attarwala, Weiping Deng, et al.. (2024). Immunostimulatory/Immunodynamic model of mRNA‐1273 to guide pediatric vaccine dose selection. CPT Pharmacometrics & Systems Pharmacology. 14(1). 42–51. 3 indexed citations
13.
14.
Figueroa, Amparo L., Gary Berman, Haiyu Zhou, et al.. (2023). 367. Safety and Immunogenicity of a 50-μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in Adolescents. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations
15.
Chalkias, Spyros, Charles Harper, Keith Vrbicky, et al.. (2023). Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19. Nature Communications. 14(1). 5125–5125. 11 indexed citations
16.
Follmann, Dean, Holly Janes, Olive D. Buhule, et al.. (2022). Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. Annals of Internal Medicine. 175(9). 1258–1265. 69 indexed citations
17.
Chu, Laurence, Keith Vrbicky, David C. Montefiori, et al.. (2022). Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nature Medicine. 28(5). 1042–1049. 56 indexed citations
18.
Chalkias, Spyros, Frank Eder, Brandon Essink, et al.. (2022). Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nature Medicine. 28(11). 2388–2397. 70 indexed citations
19.
Fallon, Eleanor A., Bethany Girard, Chun‐Shiang Chung, et al.. (2018). A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis. Journal of Leukocyte Biology. 103(6). 1151–1164. 31 indexed citations
20.
Wallemacq, Hugues, Bethany Girard, Pierre Lekeux, & Fabrice Bureau. (2010). La vaccination contre les mammites à Staphylococcus aureus chez la vache laitière. Annales de médecine vétérinaire. 154(1). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ying Chang Breakdown of academic impact, for papers by Alina Seidel Breakdown of academic impact, for papers by Maegan L. Sheehan Breakdown of academic impact, for papers by Justin DaSilva Breakdown of academic impact, for papers by Angelique Hœlzemer Breakdown of academic impact, for papers by Onosereme Ofoman Breakdown of academic impact, for papers by Cristhian Berrios Breakdown of academic impact, for papers by Meagan E. Deming
Rankless by CCL
2026